Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript
10:32am, Friday, 10'th Nov 2023
Omeros Corporation (NASDAQ:OMER ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive O
Omeros Corporation Reports Third Quarter 2023 Financial Results
04:02pm, Thursday, 09'th Nov 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
08:00am, Monday, 06'th Nov 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023,
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic st
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
08:30am, Thursday, 19'th Oct 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for
Omeros to terminate kidney disease trial as therapy fails late-stage study
08:02am, Monday, 16'th Oct 2023
Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
07:30am, Monday, 16'th Oct 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics
Omeros Corporation (OMER) Q2 2023 Earnings Call Transcript
01:28pm, Wednesday, 09'th Aug 2023
Omeros Corporation (NASDAQ:OMER ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Jennifer Williams - IR Gregory Demopulos - Co-Founder, Chairman, CEO & President Micha
Omeros Corporation Reports Second Quarter 2023 Financial Results
08:00am, Wednesday, 09'th Aug 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
08:00am, Friday, 04'th Aug 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before
Omeros Corporation - Still Looking Too Risky For A Buy Rating
05:06pm, Friday, 21'st Jul 2023
Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's lack of profitability. The company was awarded $6.6
Omeros Announces Webcast Details for Annual Meeting of Shareholders
08:30am, Wednesday, 21'st Jun 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, Ju
Why Shares of Omeros Dropped on Monday
02:47pm, Monday, 12'th Jun 2023
The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash.
Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript
10:54pm, Tuesday, 09'th May 2023
Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and CEO Mike Jacobsen - C
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
04:06pm, Thursday, 04'th May 2023
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 202
